Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 4Phase 1 1

Status

Terminated 4Withdrawn 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1Gastrointestinal 1

Conditions

Multiple Myeloma 2Recurrence 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × TIC10 compound × Clear all
NCT02863991 2024-07-03

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Jazz Pharmaceuticals

Phase 1/2 Terminated
17 enrolled 10 charts
Plasma cell

Multiple Myeloma

NCT03791398 2023-02-17

379

Brown University

Phase 1/2 Terminated
13 enrolled 11 charts
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT02420795 2022-04-04

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
16 enrolled 14 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03492138 2020-05-29

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Icahn School of Medicine at Mount Sinai

Phase 1/2 Terminated
5 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡